124 related articles for article (PubMed ID: 37148559)
1. Impact of APOE Genotype on Cognition in Idiopathic and Genetic Forms of Parkinson's Disease.
Koros C; Brockmann K; Simitsi AM; Bougea A; Liu H; Hauser AK; Schulte C; Lerche S; Pachi I; Papagiannakis N; Antonelou R; Zahou A; Wurster I; Efthymiopoulou E; Beratis I; Maniati M; Moraitou M; Michelakakis H; Paraskevas G; Papageorgiou SG; Potagas C; Papadimitriou D; Bozi M; Stamelou M; Gasser T; Stefanis L
Mov Disord; 2023 May; 38(5):907-909. PubMed ID: 37148559
[No Abstract] [Full Text] [Related]
2. Parkinson's disease is not associated with the combined alpha-synuclein/apolipoprotein E susceptibility genotype.
Khan N; Graham E; Dixon P; Morris C; Mander A; Clayton D; Vaughan J; Quinn N; Lees A; Daniel S; Wood N; de Silva R
Ann Neurol; 2001 May; 49(5):665-8. PubMed ID: 11357958
[TBL] [Abstract][Full Text] [Related]
3. The impact of Apolipoprotein E alleles on cognitive performance in patients with Parkinson's disease.
Pierzchlińska A; Białecka M; Kurzawski M; Sławek J
Neurol Neurochir Pol; 2018 Aug; 52(4):477-482. PubMed ID: 29776682
[TBL] [Abstract][Full Text] [Related]
4. Apolipoprotein E genotype in familial Parkinson's disease. The French Parkinson's Disease Genetics Study Group.
The F
J Neurol Neurosurg Psychiatry; 1997 Sep; 63(3):394-5. PubMed ID: 9328263
[TBL] [Abstract][Full Text] [Related]
5. APOE, MAPT, and COMT and Parkinson's Disease Susceptibility and Cognitive Symptom Progression.
Paul KC; Rausch R; Creek MM; Sinsheimer JS; Bronstein JM; Bordelon Y; Ritz B
J Parkinsons Dis; 2016 Apr; 6(2):349-59. PubMed ID: 27061069
[TBL] [Abstract][Full Text] [Related]
6. A molecular pathway of neurodegeneration linking alpha-synuclein to ApoE and Abeta peptides.
Gallardo G; Schlüter OM; Südhof TC
Nat Neurosci; 2008 Mar; 11(3):301-8. PubMed ID: 18297066
[TBL] [Abstract][Full Text] [Related]
7. Apolipoprotein E genotype as a risk factor for susceptibility to and dementia in Parkinson's disease.
Williams-Gray CH; Goris A; Saiki M; Foltynie T; Compston DA; Sawcer SJ; Barker RA
J Neurol; 2009 Mar; 256(3):493-8. PubMed ID: 19308307
[TBL] [Abstract][Full Text] [Related]
8. α-synuclein-lipoprotein interactions and elevated ApoE level in cerebrospinal fluid from Parkinson's disease patients.
Paslawski W; Zareba-Paslawska J; Zhang X; Hölzl K; Wadensten H; Shariatgorji M; Janelidze S; Hansson O; Forsgren L; Andrén PE; Svenningsson P
Proc Natl Acad Sci U S A; 2019 Jul; 116(30):15226-15235. PubMed ID: 31270237
[TBL] [Abstract][Full Text] [Related]
9. Exploring gene-environment interactions in Parkinson's disease.
McCulloch CC; Kay DM; Factor SA; Samii A; Nutt JG; Higgins DS; Griffith A; Roberts JW; Leis BC; Montimurro JS; Zabetian CP; Payami H
Hum Genet; 2008 Apr; 123(3):257-65. PubMed ID: 18210157
[TBL] [Abstract][Full Text] [Related]
10. Did α-Synuclein and Glucocerebrosidase Coevolve? Implications for Parkinson's Disease.
Gruschus JM
PLoS One; 2015; 10(7):e0133863. PubMed ID: 26214314
[TBL] [Abstract][Full Text] [Related]
11. Increased susceptibility to sporadic Parkinson's disease by a certain combined alpha-synuclein/apolipoprotein E genotype.
Krüger R; Vieira-Saecker AM; Kuhn W; Berg D; Müller T; Kühnl N; Fuchs GA; Storch A; Hungs M; Woitalla D; Przuntek H; Epplen JT; Schöls L; Riess O
Ann Neurol; 1999 May; 45(5):611-7. PubMed ID: 10319883
[TBL] [Abstract][Full Text] [Related]
12. Genetic impact on cognition and brain function in newly diagnosed Parkinson's disease: ICICLE-PD study.
Nombela C; Rowe JB; Winder-Rhodes SE; Hampshire A; Owen AM; Breen DP; Duncan GW; Khoo TK; Yarnall AJ; Firbank MJ; Chinnery PF; Robbins TW; O'Brien JT; Brooks DJ; Burn DJ; ; Barker RA
Brain; 2014 Oct; 137(Pt 10):2743-58. PubMed ID: 25080285
[TBL] [Abstract][Full Text] [Related]
13. Associations Between APOE Variants, Tau and α-Synuclein.
Rodriguez-Vieitez E; Nielsen HM
Adv Exp Med Biol; 2019; 1184():177-186. PubMed ID: 32096038
[TBL] [Abstract][Full Text] [Related]
14. Association between apolipoprotein E genotypes and Parkinson's disease.
Pulkes T; Papsing C; Mahasirimongkol S; Busabaratana M; Kulkantrakorn K; Tiamkao S
J Clin Neurosci; 2011 Oct; 18(10):1333-5. PubMed ID: 21782446
[TBL] [Abstract][Full Text] [Related]
15. Disease-related and genetic correlates of psychotic symptoms in Parkinson's disease.
Factor SA; Steenland NK; Higgins DS; Molho ES; Kay DM; Montimurro J; Rosen AR; Zabetian CP; Payami H
Mov Disord; 2011 Oct; 26(12):2190-5. PubMed ID: 21714002
[TBL] [Abstract][Full Text] [Related]
16. Effects of different isoforms of apoE on aggregation of the α-synuclein protein implicated in Parkinson's disease.
Emamzadeh FN; Aojula H; McHugh PC; Allsop D
Neurosci Lett; 2016 Apr; 618():146-151. PubMed ID: 26921451
[TBL] [Abstract][Full Text] [Related]
17. Lower Circulating Lymphocyte Count Predicts ApoE ε4-Related Cognitive Decline in Parkinson's Disease.
Tsukita K; Sakamaki-Tsukita H; Takahashi R
Mov Disord; 2021 Dec; 36(12):2969-2971. PubMed ID: 34647353
[No Abstract] [Full Text] [Related]
18. Neuronal ApoE Regulates the Cell-to-Cell Transmission of α-Synuclein.
Kang SJ; Kim SJ; Noh HR; Kim BJ; Kim JB; Jin U; Park SA; Park SM
Int J Mol Sci; 2022 Jul; 23(15):. PubMed ID: 35955451
[TBL] [Abstract][Full Text] [Related]
19. APOE alleles in Parkinson disease and their relationship to cognitive decline: a population-based, longitudinal study.
Kurz MW; Dekomien G; Nilsen OB; Larsen JP; Aarsland D; Alves G
J Geriatr Psychiatry Neurol; 2009 Sep; 22(3):166-70. PubMed ID: 19321880
[TBL] [Abstract][Full Text] [Related]
20. The role of APOE in cognitive trajectories and motor decline in Parkinson's disease.
Jo S; Kim SO; Park KW; Lee SH; Hwang YS; Chung SJ
Sci Rep; 2021 Apr; 11(1):7819. PubMed ID: 33837234
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
